Our team is driven to overcome the current challenges of treating people living with severe neurological disorders. We have deep experience in gene therapy research and development, cerebrospinal fluid (CSF) biofluid dynamics, bioengineering, and chemistry, manufacturing and controls (CMC). We collaborate to translate innovative science into significant therapeutic advancements for those most in need.
What we do
Alcyone is pioneering next-generation CNS precision gene-based therapeutics for complex neurological conditions. We integrate innovation in neuroscience, precision dosing and delivery, and manufacturing capabilities to deliver transformative therapies to patients.
Alcyone was established in 2012 on the premise that better delivery technology is needed to effectively treat complex neurological disorders. Alcyone built a team to overcome this complexity by harnessing the movement of CSF, engineering novel gene-based therapeutics, and revolutionizing the manufacturing of these components for world-class clinical application.
Alcyone Corporate Headquarters
Our corporate headquarters are located in Lowell, MA, just a few miles from the epicenter of US biotechnology innovation.
Process and Analytical Development Center
Our laboratory in Alachua, FL, is part of the UF Innovate - Sid Martin Biotechnology center in collaboration with the University of Florida.
Gene Therapy Development Center
Our cutting-edge gene-based therapeutics are developed in partnership with The Abigail Wexner Research Institute at Nationwide Children’s Hospital in Columbus, OH.
Falcon™ Innovation Center
The scientists developing the Falcon™ Precision Delivery System work out of our laboratory in Moscow, ID, and in collaboration with our partners at the University of Idaho.
The Alcyone team is pioneering next-generation precision gene-based therapeutics designed to transform the lives of people living with complex neurological conditions. Explore the map to learn more about our locations.